Results 191 to 200 of about 21,372 (208)

Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

Hematological Oncology, 2022
Andrew Wei, Ahmed Hamed Salem, Deanna Brackman   +2 more
exaly  

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia

International Journal of Molecular Sciences, 2022
Vladimir Vainstein, Boaz Nachmias, Adir Shaulov   +2 more
exaly  

Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax

Cancer, 2021
Naval Daver, Sanam Loghavi, Courtney D DiNardo   +2 more
exaly  

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

Oncologist, 2022
Pankit Vachhani, William Donnellan, Maika Onishi   +2 more
exaly  

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

Annals of Oncology, 2017
Jeffrey Pu, Nicole Lamanna, P M Barr
exaly  

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Annals of Oncology, 2018
Christopher R Flowers, M Kozloff, C Nolan   +2 more
exaly  

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

Journal of Clinical Pharmacology, 2016
Silpa Nuthalapati, Kevin J Freise, Ahmed Hamed Salem   +2 more
exaly  

Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors

Advances in Therapy, 2018
Ahmed Hamed Salem, Bo Tong, Suresh K Agarwal   +2 more
exaly  

Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics

European Journal of Clinical Pharmacology, 2018
Kevin J Freise, Ahmed Hamed Salem
exaly  

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure Free

Blood Advances, 2020
Brian Ball, Rami S Komrokji, Aaron D Goldberg   +2 more
exaly